Alnylam Pharmaceuticals, Inc. (ALNY) — Form 8-K: Current report

Alnylam Pharmaceuticals, Inc. filed a current report announcing that Tolga Tanguler will depart from his role as Executive Vice President, Chief Commercialization Officer in December 2026. Additionally, the company's Board of Directors authorized a program to repurchase up to $1.0 billion of its common stock. The company anticipates repurchasing approximately $500 million of common stock by the end of 2026 and the balance during 2027.